Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

被引:35
作者
Wang, Shouzheng [1 ]
Xie, Tongji [1 ]
Hao, Xuezhi [1 ]
Wang, Yan [1 ]
Hu, Xingsheng [1 ]
Wang, Lin [1 ]
Li, Yan [2 ]
Li, Junling [1 ]
Xing, Puyuan [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Natl Clin Res Ctr Canc,Dept Pathol, Beijing, Peoples R China
关键词
anti-angiogenesis; epidermal growth factor receptor mutation; lung adenocarcinoma; small cell histological transformation; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITORS; BEVACIZUMAB; RESISTANCE; CARCINOMAS; RB1;
D O I
10.1111/1759-7714.14144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patients and explore the treatment modes after transformation. Methods EGFR-mutant LADC patients with SCLC transformation were retrospectively included in the study. Demographic and clinical data were collected. Survival outcomes and corresponding influential factors were analyzed. Results Twenty-nine patients were included in the study. The median progression-free survival (PFS) of patients who received first-line EGFR-TKIs was 13.1 months. The median time to SCLC transformation was 27.5 months. After transformation, the objective response rates of patients who received first-line chemotherapy with or without EGFR-TKIs were 43.8% and 37.5%, respectively. The median PFS of patients reveiving chemotherapy with EGFR-TKIs was significantly longer than that of patients receiving chemotherapy without EGFR-TKIs (5.2 vs. 3.0 months; HR, 0.19; 95% CI: 0.05-0.72; p = 0.014). However, there was no significant difference in median overall survival (OS) between patients who received chemotherapy with or without EGFR-TKIs (14.8 vs. 13.0 months; p = 0.474). In the multivariate Cox proportional hazards regression analysis, both anti-angiogenic treatment (HR, 0.04; 95% CI: 0.01-0.29; p = 0.001) and local radiotherapy (HR, 0.28; 95% CI: 0.08-0.97; p = 0.044) were significantly associated with better patient OS after transformation. Conclusions Compared with chemotherapy alone, the combination of chemotherapy and EGFR-TKIs as first-line treatment after SCLC transformation can benefit patients in PFS but not in OS. However, anti-angiogenic therapies and local radiotherapy can significantly prolong OS after transformation.
引用
收藏
页码:2585 / 2593
页数:9
相关论文
共 25 条
[1]   Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases [J].
Ahn, Soomin ;
Hwang, Soo Hyun ;
Han, Joungho ;
Choi, Yoon-La ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil ;
Ahn, Myung-Ju ;
Park, Woong-Yang .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2016, 50 (04) :258-263
[2]   Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review [J].
Chen, Shen ;
He, Yayi ;
Liu, Juan ;
Chen, Xiaoxia ;
Yu, Jia ;
Li, Wei ;
Chen, Bin ;
Sun, Chenglong ;
Zhou, Caicun .
ONCOTARGETS AND THERAPY, 2019, 12 :11305-11311
[3]  
Cheng Y., 2021, BRIT J CANCER, V18, P1
[4]   Comprehensive molecular profiling of lung adenocarcinoma [J].
Collisson, Eric A. ;
Campbell, Joshua D. ;
Brooks, Angela N. ;
Berger, Alice H. ;
Lee, William ;
Chmielecki, Juliann ;
Beer, David G. ;
Cope, Leslie ;
Creighton, Chad J. ;
Danilova, Ludmila ;
Ding, Li ;
Getz, Gad ;
Hammerman, Peter S. ;
Hayes, D. Neil ;
Hernandez, Bryan ;
Herman, James G. ;
Heymach, John V. ;
Jurisica, Igor ;
Kucherlapati, Raju ;
Kwiatkowski, David ;
Ladanyi, Marc ;
Robertson, Gordon ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Sinha, Rileen ;
Sougnez, Carrie ;
Tsao, Ming-Sound ;
Travis, William D. ;
Weinstein, John N. ;
Wigle, Dennis A. ;
Wilkerson, Matthew D. ;
Chu, Andy ;
Cherniack, Andrew D. ;
Hadjipanayis, Angela ;
Rosenberg, Mara ;
Weisenberger, Daniel J. ;
Laird, Peter W. ;
Radenbaugh, Amie ;
Ma, Singer ;
Stuart, Joshua M. ;
Byers, Lauren Averett ;
Baylin, Stephen B. ;
Govindan, Ramaswamy ;
Meyerson, Matthew ;
Rosenberg, Mara ;
Gabriel, Stacey B. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Kim, Jaegil ;
Stewart, Chip .
NATURE, 2014, 511 (7511) :543-550
[5]   Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 [J].
Horn, Leora ;
Dahlberg, Suzanne E. ;
Sandler, Alan B. ;
Dowlati, Afshin ;
Moore, Dennis F. ;
Murren, John R. ;
Schiller, Joan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6006-6011
[6]   Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group [J].
Jalal, Shadia ;
Bedano, Pablo ;
Einhorn, Lawrence ;
Bhatia, Sumeet ;
Ansari, Rafat ;
Bechar, Naftali ;
Koneru, Karuna ;
Govindan, Ramaswamy ;
Wu, Jingwei ;
Yu, Menggang ;
Schneider, Bryan ;
Hanna, Nasser .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) :2008-2011
[7]   Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Jett, James R. ;
Schild, Steven E. ;
Kesler, Kenneth A. ;
Kalemkerian, Gregory P. .
CHEST, 2013, 143 (05) :E400-E419
[8]   Transformation of NSCLC to SCLC after 1st-and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib 2 CARE-compliant case reports [J].
Lai, Lin ;
Meng, Wentao ;
Wei, Jialiang ;
Zhang, Xiaofei ;
Tan, Zhiwei ;
Lu, Yunxin ;
Hou, Encun .
MEDICINE, 2021, 100 (10) :e25046
[9]   Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas [J].
Lee, June-Koo ;
Lee, Junehawk ;
Kim, Sehui ;
Kim, Soyeon ;
Youk, Jeonghwan ;
Park, Seongyeol ;
An, Yohan ;
Keam, Bhumsuk ;
Kim, Dong-Wan ;
Heo, Dae Seog ;
Kim, Young Tae ;
Kim, Jin-Soo ;
Kim, Se Hyun ;
Lee, Jong Seok ;
Lee, Se-Hoon ;
Park, Keunchil ;
Ku, Ja-Lok ;
Jeon, Yoon Kyung ;
Chung, Doo Hyun ;
Park, Peter J. ;
Kim, Joon ;
Kim, Tae Min ;
Ju, Young Seok .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) :3065-+
[10]   Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review [J].
Leonetti, Alessandro ;
Minari, Roberta ;
Mazzaschi, Giulia ;
Gnetti, Letizia ;
La Monica, Silvia ;
Alfieri, Roberta ;
Campanini, Nicoletta ;
Verze, Michela ;
Olivani, Andrea ;
Ventura, Luigi ;
Tiseo, Marcello .
FRONTIERS IN ONCOLOGY, 2021, 11